Fig. 2.

a Western blotting analysis of pEGFR and EGFR in whole lysates of RAW 264.7 cells incubated, for 6 days, with MM1.S derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml), with rhAREG (50 μg/ml) and rhRANKL (25 μg/ml). The histogram on the right represents the ratio pEGFR/EGFR, based on densitometric analysis normalized versus GAPDH, used as loading control. b Evaluation by quantitative real-time PCR of mRNA expression of SNAIL in RAW 264.7 incubated, for 3 and 6 days, with MM1.S-derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml), rhRANKL (25 μg/ml), and rhAREG (50 μg/ml). Human PB CD14⁺ cells incubated for 6 days in osteoclastogenic medium (rhRANKL 25 ng/ml and MCSF 25 ng/ml), with MM1.S derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml). *Exo vs untreated (**p ≤ 0.01; ***p ≤ 0.001); ^#Exo+AREG mAb vs Exo (^#p ≤ 0.05)